Dublin (IE), Cambridge (UK), Brisbane (AU) | 18 December 2019: Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, is delighted to announce that Chief Executive Officer, Professor Matt Cooper, has been admitted as an Honorary Fellow to the prestigious Royal Society of Chemistry. The Society was founded in 1841, when 77 scientists, including doctors, academics, manufacturers and entrepreneurs came together with a common mission to leverage academic excellence to advance the chemical sciences.
Professor Cooper is a scientific entrepreneur with a track record of innovation in the development of therapies that block harmful inflammation and solutions to combat superbugs (antibiotic-resistant bacteria), both of which affect millions of people globally. He was a full-time career academic between 2009-2016, discovering several new antibiotics and pioneering methods to rapidly identify infections. He founded the Centre for Superbug Solutions and the Community for Open Access Antimicrobial Drug Discovery (CO-ADD) at the University of Queensland, Australia and has published more than 350 scientific papers and 50 patents and patent applications. Concurrently, his work into inflammation has resulted in over 40 publications on the NLRP3 inflammasome, marking substantial progress in the field.
Professor Cooper obtained his Ph.D. in Organic Chemistry and B.Sc. Honours Degree (First Class), from the University of Adelaide, Australia. He was a Postdoctoral Fellow with Professor Dudley Williams, at the Cambridge Centre for Molecular Recognition, University of Cambridge, UK; and was a Senior Consultant at Biacore AB in Sweden. Professor Cooper was also a Postdoctoral Fellow with Prof Chris Abell, Cambridge Centre for Molecular Recognition at the University of Cambridge, UK. He is a National Health and Medical Research Council (NHMRC) Australia Fellow, a Professor of Chemical Biology at the Institute of Molecular Bioscience, and an Affiliate Professor in the School of Chemistry and Molecular Biology at The University of Queensland. Since 2016, Professor Cooper has been the Chief Executive Officer of Inflazome, which he co-founded with Professor Luke O’Neill of Trinity College Dublin.
Contacts
Inflazome:
Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
Media:
FTI Consulting
UK & International | Ciara Martin/Tim Stamper
T: +44 20 37271000
Ireland & International | Jonathan Neilan/Patrick Berkery
T: +353 1 7650800